Global G-CSF Biosimilars Market Size By Type (Human Growth Hormone, Erythropoietin), By Application (Blood Disorders, Oncology Diseases), By Region, And Segment Forecasts, 2023 to 2032

lobal G-CSF Biosimilars Market Report Description

The Global G-CSF (Granulocyte Colony-Stimulating Factor) Biosimilars Market was valued at USD 745 million in 2023 and is projected to reach USD 1.42 billion by 2031, expanding at a CAGR of 8.3% during the forecast period from 2023 to 2031. The market is gaining momentum due to the rising incidence of neutropenia in cancer patients undergoing chemotherapy, increased healthcare expenditure, and cost-saving benefits associated with biosimilars. G-CSF biosimilars, primarily used to stimulate the production of white blood cells, are proving vital in reducing infection risks and enabling uninterrupted cancer treatments.

Drivers:

1. Growing Cancer Burden Worldwide:

The increasing prevalence of cancer globally is directly contributing to the demand for supportive therapies like G-CSF. With chemotherapy-induced neutropenia being a common complication, biosimilars are becoming essential in improving patient outcomes and reducing hospitalization rates.

2. Patent Expiry of Biologics and Favorable Regulatory Framework:

Several blockbuster biologics, including original G-CSF drugs like Neupogen and Neulasta, have lost patent protection, opening the door for biosimilar alternatives. Regulatory agencies such as the FDA and EMA are streamlining approval pathways, encouraging biosimilar development and adoption.

3. Cost-Effectiveness of Biosimilars:

G-CSF biosimilars offer significant cost savings compared to their reference biologics. This is especially beneficial for healthcare systems in low- and middle-income countries, accelerating global access to essential oncology support drugs.

Restraints:

1. Market Skepticism and Physician Reluctance:

Despite regulatory approvals, physicians in some regions remain cautious about prescribing biosimilars due to perceived differences in efficacy and safety. This hesitancy can impede market penetration.

2. Complex Manufacturing and Regulatory Compliance:

The production of biosimilars involves intricate biological processes, demanding significant investment in quality assurance, clinical trials, and regulatory compliance. Smaller manufacturers may find these barriers challenging.

Opportunity:

1. Rising Demand in Emerging Markets:

Emerging economies, particularly in Asia-Pacific and Latin America, are experiencing rapid growth in biosimilar uptake. Government support, improving healthcare infrastructure, and the push for cost containment create favorable conditions for market expansion.

2. Expansion of Indications and Combination Therapies:

Ongoing clinical trials are evaluating G-CSF biosimilars for expanded indications beyond oncology, such as for patients with HIV/AIDS or undergoing bone marrow transplants. These advancements could further widen the market scope.

Market by System Type Insights:

The Filgrastim biosimilars segment dominated the market in 2023, driven by their earlier market entry and well-established clinical performance. However, Pegfilgrastim biosimilars are projected to witness the fastest growth due to their once-per-cycle dosing advantage and increasing adoption in developed markets.

Market by End-use Insights:

Hospital pharmacies represented the largest share of the G-CSF biosimilars market in 2023, owing to their role in chemotherapy support and immediate access to critical medications. The retail pharmacy segment is anticipated to grow steadily, supported by increased outpatient treatments and growing awareness among end-users.

Market by Regional Insights:

North America held the dominant share in 2023, benefiting from robust healthcare infrastructure, regulatory clarity, and early biosimilar adoption. Meanwhile, the Asia-Pacific region is expected to register the highest CAGR during the forecast period, led by countries like India, China, and South Korea where biosimilars are rapidly gaining ground due to cost constraints and local production capabilities.

Competitive Scenario:

Prominent players in the global G-CSF biosimilars market include Pfizer Inc., Novartis AG (Sandoz), Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Mylan N.V., and Biocon Biologics Ltd. These companies are focusing on expanding their product portfolios, entering new geographies, and conducting post-marketing surveillance to ensure long-term safety and efficacy.

Scope of Work – Global G-CSF Biosimilars Market

Key Market Developments:

2023: Coherus BioSciences launched Yusimry™, a biosimilar to Neulasta, with significant pricing advantages in the U.S. market.

2024: Novartis’ Sandoz division expanded its biosimilar production capacity in Europe to meet rising demand.

2025: Dr. Reddy’s Laboratories entered into a licensing agreement with a Japanese pharma firm to commercialize G-CSF biosimilars in the Asia-Pacific region.

FAQs:

1. What is the current market size of the Global G-CSF Biosimilars Market?

The Global G-CSF Biosimilars Market was valued at USD 745 million in 2023.

2. What is the major growth driver of the Global G-CSF Biosimilars Market?

The major growth driver is the rising incidence of chemotherapy-induced neutropenia and the cost-effectiveness of biosimilars.

3. Which is the largest region during the forecast period in the Global G-CSF Biosimilars Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to grow the fastest.

4. Which segment accounted for the largest market share in Global G-CSF Biosimilars Market?

Filgrastim biosimilars accounted for the largest share in 2023.

5. Who are the key market players in the Global G-CSF Biosimilars Market?

Key players include Pfizer, Novartis (Sandoz), Teva, Coherus BioSciences, Intas, Dr. Reddy’s, Mylan, and Biocon.

Let me know if you'd like this in DOCX or PDF format.